Neurocrine Biosciences (NBIX) Shares Outstanding (Weighted Average) (2010 - 2026)

Neurocrine Biosciences has reported Shares Outstanding (Weighted Average) for 17 years, with the latest figure at $100.5 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding (Weighted Average) rose 0.8% year-over-year to $100.5 million; the trailing twelve-month figure through Mar 2026 stood at $100.5 million (up 0.8% YoY), and the FY2025 full-year result was $99.5 million, down 0.9% from the prior year.
• Shares Outstanding (Weighted Average) for Q1 2026 stood at $100.5 million, up from $99.5 million in the prior quarter.
• The five-year high for Shares Outstanding (Weighted Average) was $101.1 million in Q3 2024, with the low at $95.3 million in Q1 2022.
• Historically, Shares Outstanding (Weighted Average) has averaged $98.4 million across 5 years, with a median of $99.0 million in 2025.
• Annual changes were most pronounced in 2024 — Shares Outstanding (Weighted Average) climbed 3.49% — and 2025, when it decreased 1.79%.
• Neurocrine Biosciences' Shares Outstanding (Weighted Average) stood at $95.8 million in 2022, then rose by 1.98% to $97.7 million in 2023, then grew by 2.76% to $100.4 million in 2024, then dropped by 0.9% to $99.5 million in 2025, then grew by 1.01% to $100.5 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $100.5 million (Q1 2026), $99.5 million (Q4 2025), and $99.3 million (Q3 2025), per Business Quant data.